Comparing tailored vs. standard treatment for active Takayasu's arteritis.
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with active Takayasu's arteritis (NIH score of 2 or more).
- If you are female, you must have a negative pregnancy test and agree not to become pregnant during the trial.
- If you are taking steroids (prednisone or similar), your dose is stable and no more than 0.6 mg per kg of body weight per day.
- You are willing to stop any other arthritis medications for a specific period before starting the trial, as directed.
- You do not have active infections like hepatitis B, active tuberculosis, or cancer.
- You do not have severe organ failure or other autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
This trial tests a medication called secukinumab for people with active, severe Takayasu arteritis, a disease that causes inflammation in large blood vessels. The goal is to see if secukinumab can help control the disease better than standard treatments alone.
This trial tests whether pirfenidone, a medication used for lung scarring, can reduce scarring (fibrosis) in the arteries of people with Takayasu arteritis. It aims to slow disease progression and improve blood vessel health.
This study tests two new medications, vunakizumab and ivarmacitinib, for people with active Takayasu's arteritis (TAK) that is not fully controlled by standard treatments. The goal is to see if these drugs are safe and effective for reducing disease activity.
Hear when a new Takayasu Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.